All In Biotech

Drug Trial Radar · NCT07913074

A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.

A Phase 2a, Randomized, Double-Masked, Double-Dummy, Parallel-Group Study to Evaluate the Intraocular Pressure (IOP)-Lowering Efficacy, Safety, and Tolerability of TB0001 (Pregabalin Ophthalmic Solution) Compared With Timolol 0.5% In Subjects With Primary Open-Angle Glaucoma (POAG) Or Ocular Hypertension (OHT)

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Oct 23, 2026

Primary completion

Jun 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Tavo BiotherapeuticsIndustry
Sponsor type
Industry
Collaborators
True North Therapeutics
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is evaluating a new eye drop containing pregabalin (TB0001) as a potential treatment for people with primary open-angle glaucoma or ocular hypertension. The study aims to determine whether TB0001 lowers eye pressure as effectively as timolol, a commonly used glaucoma eye drop, while remaining safe and well tolerated. Participants will be randomly assigned to receive one of three strengths of TB0001 or timolol for 28 days. Eye pressure, eye health, side effects and tolerability will be assessed throughout the study. The results will help identify the most appropriate dose of TB0001 for future clinical studies.

Conditions

  • Primary Open - Angle Glaucoma (POAG)
  • Ocular Hypertension (OHT)

Interventions

  • Arm 1: TB0001 ophthalmic solution 0.9%Drug

    TB0001 is a sterile, clear colorless to slightly yellow pregabalin ophthalmic solution at concentrations of 0.9%

  • Arm 2: TB0001 ophthalmic solution 1.2%Drug

    Pregabalin ophthalmic solution (TB0001) 1.2% is a sterile, colorless to slightly yellow solution.

  • TB0001 ophthalmic solution 1.5%Drug

    TB0001 is a sterile, clear, colorless to slightly yellow solution

  • Timolol 0.05% eye dropsDrug

    Timolol ophthalmic solution 0.5% will be administered twice daily (AM + PM)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from mean diurnal baseline IOP to mean diurnal IOP at Day 28Time frame: Baseline (pre-treatment) and Day 28 (approximately 1, 3 and 6 hours after the morning study treatment administration; primary timepoint). Baseline mean diurnal intraocular pressure is calculated from measurements obtained prior to treatment initiation.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Global Research Management, Inc

    Glendale, California · Recruiting

  • Eye Research Foundation, Inc

    Newport Beach, California · Recruiting

  • Piedmont Eye Center

    Lynchburg, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.